Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04541329 · ClinicalTrials.gov registry record · Phase 4
Predicting Inflammatory Skin Disease Response to IL-23 Blockade
A Phase 4 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 7
- Enrollment target
NCT04541329: Completed Phase 4 study, sponsored by University of California, San Francisco.
NCT04541329 is a Phase 4 study that has completed, run by University of California, San Francisco. The registered enrollment target is 7 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04541329, a Phase 4 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study examines the effect of IL-23 blockade with Tildrakizumab on the immune cells of psoriatic skin lesions.
Primary Outcome
Psoriasis Area and Severity Index (PASI) is a measure of psoriasis severity. The maximum score is 72, minimum score is 0. The higher the number, the more severe the psoriasis is.
Interventions
- BIOLOGICAL Tildrakizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2020-09-16 |
| Est. Completion | 2023-01-15 |
| Phase | Phase 4 |
What the finished NCT04541329 record still lists
NCT04541329 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Tildrakizumab is the first listed.
NCT04541329 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04541329 about?
NCT04541329 is a clinical study titled "Predicting Inflammatory Skin Disease Response to IL-23 Blockade". This study examines the effect of IL-23 blockade with Tildrakizumab on the immune cells of psoriatic skin lesions.
What is the current status of trial NCT04541329?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 7 participants. The study started on 2020-09-16. Estimated completion is 2023-01-15.
What interventions are being tested in trial NCT04541329?
The interventions under investigation include: Tildrakizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04541329?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04541329's enrollment target sits among peer trials
7 1981st of 2000 higher than 18 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI